Saracatinib synergizes with enzalutamide to downregulate androgen receptor activity in castration resistant prostate cancer

We performed RNA-seq to evaluate the consequence of saracatinib's effects on androgen receptor residue Y534 as it pertains to Androgen Receptor gene signatures Performed gene expression profiling analysis using data obtained from RNA-seq of 1 cell line at 4 treatment groups. In duplicate